| Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. | |
| | |
MedLine Citation:
|
PMID: 22136831 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: There are limited data on the utility of 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) and (18)F-2-deoxy-d-glucose ((18)F-FDG) in the workup of patients with pancreatic neuroendocrine tumors (PNETs). The aim of our study was to determine the accuracy of (18)F-DOPA and (18)F-FDG to detect PNETs in patients with von Hippel-Lindau disease (vHL). METHODS: We studied prospectively 69 patients with a diagnosis of vHL and pancreatic lesion(s) using computed tomography (CT), magnetic resonance imaging (MRI), (18)F-FDG, and (18)F-DOPA. Clinical, genetic, and laboratory characteristics were analyzed to determine association with imaging study results. RESULTS: In sum, 40 patients underwent evaluation by all 4 modalities; 98 PNETs and 55 PNETs were identified on CT and MRI, respectively. Only 11 of the 98 lesions (11%) were positive on (18)F-DOPA and 45 of the 98 (46%) lesions were positive on (18)F-FDG. There were 13 (18)F-DOPA and 26 (18)F-FDG avid extrapancreatic lesions. One patient underwent resection of an (18)F-DOPA avid extrapancreatic lesion in the lung, with pathology demonstrating a NET. There was no association between (18)F-DOPA and (18)F-FDG avidity and tumor size, age, gender, vHL mutation, or serum chromogranin A level. CONCLUSION: (18)F-FDG and MRI may be adjuncts to CT in identifying PNETs and metastatic disease. (18)F-DOPA has limited value in identifying PNETs in patients with vHL, but may be useful for identifying extrapancreatic NET lesions. |
| | |
Authors:
|
Mio Kitano; Corina Millo; Reza Rahbari; Peter Herscovitch; Krisana Gesuwan; Richard C Webb; Aradhana M Venkatesan; Giao Q Phan; Marybeth S Hughes; Steven K Libutti; Naris Nilubol; William M Linehan; Electron Kebebew |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: Surgery Volume: 150 ISSN: 1532-7361 ISO Abbreviation: Surgery Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-05 Completed Date: 2012-02-06 Revised Date: 2012-03-05 |
Medline Journal Info:
|
Nlm Unique ID: 0417347 Medline TA: Surgery Country: United States |
Other Details:
|
Languages: eng Pagination: 1122-8 Citation Subset: AIM; IM |
Copyright Information:
|
Published by Mosby, Inc. |
Affiliation:
|
Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, 10 Center Drive, Bethesda, MD 20892, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Dopamine / analogs & derivatives*, diagnostic use Female Fluorodeoxyglucose F18 / diagnostic use* Humans Magnetic Resonance Imaging* Male Middle Aged Neuroendocrine Tumors / complications, diagnosis* Pancreatic Neoplasms / complications, diagnosis* Positron-Emission Tomography Prospective Studies Radiopharmaceuticals / diagnostic use* Tomography, X-Ray Computed Young Adult von Hippel-Lindau Disease / complications* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 59043-70-8/6-fluorodopamine; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Population-level predictors of persistent hyperparathyroidism.
Next Document: Zollinger-Ellison syndrome associated with a history of alcohol abuse: Coincidence or consequence?